Incyte Corp (INCY) Gets a Buy Rating from Cowen & Co.


Cowen & Co. analyst Marc Frahm maintained a Buy rating on Incyte Corp (INCY) today. The company’s shares closed last Monday at $72.55.

According to TipRanks.com, Frahm is a 1-star analyst with an average return of -5.4% and a 44.0% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Magenta Therapeutics Inc, and Applied Therapeutics Inc.

Incyte Corp has an analyst consensus of Moderate Buy, with a price target consensus of $93.90.

See today’s analyst top recommended stocks >>

Incyte Corp’s market cap is currently $15.86B and has a P/E ratio of 52.15. The company has a Price to Book ratio of 7.05.

Based on the recent corporate insider activity of 101 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts